Meta-analyses of these and other ICI clinical trials in RCC, including 4635 patients treated with a variety of checkpoint inhibitors, showed that overall survival failed to associate with PD-L1 expression levels [160]. This evidence concerns the gene CD274 and renal cell carcinoma.